AYTU BioPharma

AYTU

Valor de mercado US$ 22,2 mi

ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026 EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026 $26.3 million cash balance at June 30, 2026 Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m.

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:15 a.m.

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript